Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of upadacitinib in adults with moderate to severe atopic dermatitis
NL-OMON45624Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of upadacitinib in atopic dermatitis (AD) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Mean percent change from baseline in EASI score at Week 16. Started Jan 2017; status: completed.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON45624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45624.